menu

NEWS

Platomics and biocrates announce strategic collaboration: A Game-Changer for the adoption of metabolomics 

Innsbruck and Vienna, Austria, March 11, 2025 – biocrates life sciences AG, a global leader in quantitative metabolomics, and regulatory automation provider Platomics announce a strategic collaboration to support laboratories with ensuring and documenting the quality of their workflows with biocrates metabolomics solutions. biocrates’ metabolomics kits—which can quantify up to hundreds of metabolites across key biological pathways—are registered on Platomics’ state-of-the-art digital regulatory PlatoX® platform and can be effortlessly incorporated into the technical documentation of laboratory workflows. This partnership contributes to ensuring highly reproducible quantitative results and comprehensive standardized documentation for workflows which are also faster in service—with less effort...

READ MORE
Platomics and Sequentia Biotech – Strategic Collaboration to Advance Precision Diagnostics

Vienna, Austria, June 26, 2025 – Platomics and Sequentia Biotech, innovator in AI-driven genomic data interpretation, partnered to collaborate on streamlining the clinical diagnostics pipeline. This partnership combines Platomics’ PlatoX® for managing regulatory workflows and data integration with Sequentia’s advanced analytics capabilities for omics data interpretation. The joint effort will focus on equipping laboratories and clinicians with advanced capabilities to perform high-throughput diagnostic testing with increased accuracy, regulatory compliance, and operational efficiency.  Sequentia’s products will be registered on Platomics’ ecosystem to provide product data supporting laboratories in achieving test compliance according to the latest EU IVDR requirements.  About Sequentia Biotech...

READ MORE
Pillar Biosciences and Platomics Announce Collaboration to Support EU Clinical Labs with Documentation of NGS Workflows

Natick, Massachusetts, USA and Vienna, Austria, September 4, 2025 – Pillar Biosciences, a leading provider of kitted next-generation sequencing (NGS) panels, and regulatory automation provider Platomics are collaborating to streamline compliance for next-generation sequencing (NGS) tests under the EU’s In Vitro Diagnostic Regulation (IVDR).    Now that IVDR has come into force, clinical laboratories must provide extensive regulatory documentation. Labs are often challenged to manage the time, expertise, and resources necessary to meet these rigorous regulatory demands. Through this initiative, Pillar’s customers will benefit from the PlatoX® platform, which offers a structured system to complete their documentation based on direct product data, integrated...

READ MORE
Platomics Inks Deals With Sophia Genetics, Agilent for Automated IVDR Compliance Documentation

Jan 09, 2025 | genomeweb NEW YORK – Regulatory compliance software provider Platomics said Thursday that it has launched a pilot program with Agilent Technologies to offer customers laboratory documentation capabilities for next-generation sequencing tests developed under the European Union’s In Vitro Diagnostic Regulation (IVDR).  Separately, the Vienna-based firm said Wednesday that it has inked a partnership with Sophia Genetics to streamline the compliance documentation process for EU clinical laboratories developing NGS tests using Sophia’s products. Financial details for the two deals were not disclosed.  Through the collaboration, Agilent customers developing NGS tests can leverage Platomics’ PlatoX platform to generate documentation required...

READ MORE
NeuroKaire Closes $10M Funding Round 

Kearny, NJ. — Dec. 17, 2024 — NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, has successfully secured $10 million in funding to advance development of its clinical test which helps identify drug efficacy for depression patients. The funding will help the company scale operations and further expand pharmaceutical partnerships. GreyBird Ventures led the round and the company’s other investors include Meron Capital and Jumpspeed Ventures, among others.  Based on a simple blood draw, NeuroKaire can provide a new view into brain function, including drug response insights that are based on the combined neurobiology and clinical...

READ MORE
NeuroKaire Receives Clinical Laboratory Improvement Amendments Certification 

Comprehensive pharmacogenetic assay focused on psychiatry and neurology advances precision medicine for the brain. November 20, 2024 // PR Newswire NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, announced today that its Kearny, NJ-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.   NeuroKaire’s new CLIA laboratory’s first offering is a pharmacogenetic assay focused on psychiatric and neurological drugs. Pharmacogenetics is the study of the interaction between genetic variations and drug response. The comprehensive test analyzes 95 variants...

READ MORE
1 2 3 10
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER